- EMA Recommends Granting a Marketing Authorisation for Hybrid Methotrexate
- EMA Recommends Extension of Indications for Lenalidomide in Multiple Myeloma
- NICE Issues Technology Appraisal Guidance for Ibrutinib for Previously Treated CLL and Untreated CLL with 17p Deletion or TP53 Mutation
- NICE Issues Recommendations for Pomalidomide in Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib
- Ibrutinib, First FDA-Approved Therapy for Marginal Zone Lymphoma
- Press Release: Biosimilars Create Opportunities for Sustainable Cancer Care
- FDA Approves Bevacizumab Plus Chemotherapy, Followed by Bevacizumab Alone, for the Treatment of Patients with Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- NICE Recommends Pertuzumab for the Neoadjuvant Treatment of HER2-positive Breast Cancer
- EMA Adopts a New Indication for 5-Aminolevulinic Acid
- EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Chlormethine
- FDA Grants Accelerated Approval to Rucaparib for Previously Treated, BRCA Mutated Advanced Ovarian Cancer
- EMA Recommends Granting a Marketing Authorisation for Biosimilar Rituximab
- ESMO Asia 2016 Press Release: Depressed Patients Are Less Responsive to Chemotherapy
- EMA Recommends Granting a Conditional Marketing Authorisation for Alectinib for the Treatment of ALK-Positive Advanced NSCLC
- Clinical Responses and Mutation Clearance After Decitabine in Patients with AML and MDS
- PI3K Inhibitor Buparlisib in Combination with Fulvestrant Prolongs PFS Compared to Placebo Plus Fulvestrant
- PFS Significantly Longer With Osimertinib Than With Platinum-Pemetrexed in EGFR T790M-Positive Advanced NSCLC
- FDA Approves Daratumumab in Combination with Lenalidomide and Dexamethasone or Bortezomib and Dexamethasone for Multiple Myeloma Treatment
- EMA Recommends Extension of Therapeutic Indications for Ofatumumab
- EMA Recommends Extension of Therapeutic Indications for Vandetanib
- NICE Does Not Recommend Cobimetinib in Combination With Vemurafenib
- NICE Recommends Osimertinib for Advanced EGFR T790M Mutation-Positive NCSLC
- EMA Recommends a Change to the Terms of the Marketing Authorisation for Arsenic Trioxide
- Off-Label Drug Coverage in Oncology
- FDA Grants Accelerated Approval to New Treatment for Advanced STS